# AbbVie Pays 10.9 Billion for Apogee as Pharma M&A Hits a Deal a Week - The Biotech Patent Cliff & M&A - Week of June 26, 2026 > Biotech patent-cliff M&A newsletter for the week of June 26, 2026. AbbVie's $10.9B all-cash Apogee buy (49% premium, no CVR) became 2026's largest biopharma-proper takeout as a J.P. Morgan banker described large-cap pharma closing almost a deal a week, with XBI at five-year highs and the busiest biotech IPO year since 2021 at the halfway mark. ## The Biotech Patent Cliff & M&A ### Week of June 26, 2026: AbbVie Pays 10.9 Billion for Apogee as Pharma M&A Hits a Deal a Week --- Pharma is no longer doing acquisitions. It's doing a standing order. This week AbbVie put down $10.9 billion for Apogee Therapeutics, a 49% premium, all cash, no CVR, and a J.P. Morgan banker put words to what the tape has been screaming for a month: large-cap pharma is now closing "almost a deal every week." The cliff is the engine, and nobody's lifting off the gas. **TL;DR** - **AbbVie buys Apogee (APGE) for $10.9B**, $135/share, a 49% premium, expected to close Q3. It's AbbVie's biggest deal since Allergan, it doubles down on the post-Humira immunology playbook, and it's now the largest "biopharma proper" takeout of 2026. - **The cadence is the story.** J.P. Morgan's healthcare IB chief says large caps are doing "a deal every week," that LOEs drive the whole cycle, and, the line that should worry value buyers, that pharma investors are "relatively price insensitive" about what their companies pay. - **The window is wide open.** XBI sits at five-year highs, this is already the most active biotech IPO year since 2021 at the halfway mark, and the Street notched both the largest-ever biotech follow-on and the largest-ever biotech IPO in a single week. **What's new** **AbbVie's Apogee buy is the new high-water mark.** On BioCentury This Week, ["Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjdr3kjf1wC5aeHbajJMDr59j6kWQTbIxYct2u0tMx4-2FSxBmGPTNY0VjsYotuA-2BK4lnvCsIi4kw8vVYaYzqQxyzH4-2B044tMJUsyolRsb2iuhQ-3D-3DdSFR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpQcSdrZp8rmS649peUmOlpuzHkIoJPK40iybXOVMl0UrZsnGFZCXchvmB33d-2Bh7cYxSAnhZq72sOWvRI6WJgywlpr099O2tSwSs1ME-2FrBWX5wJeOfaDieh4A6NjDS4JTmQ-3D-3D) (June 23), news editor Paul Bananos sized it up: "here's an 11-digit takeout, actually even a little bigger than Immunogen or Cerevel. It's $10.9 billion. And it's in immunology, which is AbbVie's biggest therapeutic area in terms of revenue right now." BioSpace's Heather McKenzie, on ["AbbVie keeps M&A rolling…"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgVrMDLRFNPiGHgH-2BBvU-2B97R2yawKv7u8ab2-2B3oF2P8C2PvmJKzSMA6Y7xhaXecKtAc3Ae40yhP61dOPBDjg5uqaLwADbp-2FulF-2BsHDRCVKBRA-3D-3DGWab_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpTq2pqxI9UHqSRkJHF3UW-2F7m8E7UJ4ADR-2B7E7q3LCfrLhqgD-2F6GRCun8F6tSVl4830XLxcHFO7bHNJAdYYxL8TYsgQ401jAmHHPeSkrAtbqkp-2BUVnEHxkzl17hWuRbhv5g-3D-3D) (June 24), put it in league-table context: the deal "has actually displaced that GSK Nuvalent deal as the year's second biggest behind Sun Pharma's $11.75 billion gamble for Organon in April. And it's really the largest in what I would call, quote, biopharma proper." Terms, via Brew Markets' ["Big Pharma's 'Patent Cliff'"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgZ-2Ft4RfwD-2Bqz2n9fw-2BbHEUmJ8lfYbhkm5-2F-2BxwwL7lVygaOvi9hbaXeo7iFCC0bmGLpOyzQvXtvhwjLW5fP3J-2F1PwmyhnDn0iI0328wFJczGw-3D-3DqfKB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpfvj3WivoCXydjmkfB0HUbkezkQ3TKy-2FfMdveE8lBxuXnezj-2BO2bV-2BBoPJu29k-2FgsjZXS-2BblVTBorscXAULpZozCk-2FVqDYC-2F-2BKwlOD5QBCAAGLZuJNpbuYd54hpxpREVsQ-3D-3D): "$135 a share in cash, a 49% premium to Apogee's Thursday closing price of $90." **This is the Humira playbook, run again.** The numbers behind AbbVie's urgency are stark. Per Crain's Daily Gist ([June 23](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh2gA9vYJzOvpKSmtw1f1L1RFxwEWB31ucOELA6JE7Mcjc6WIjIOqgHdgnJzVBFR6-2FXgGjpkiLh8RX6oCtxYMmnONsz5znyraZqYXBdGETY4Q-3D-3DB0-w_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpeqJYoGZeRlQ-2B816iK-2FTskO8HGGqoreaXtCDVGVxBgBbDWG-2Bll50qmHjZRW9b3r8RLAX62G4aU7WFtQpYqj0mRpKmipi3HYPzNt5Fkrju-2B73fZ8Mghr1UlNctgCqpoxiZw-3D-3D)): "Humira revenues are falling, down nearly 40 percent to $688 million in the quarter… Skyrizi's net revenues were at $4.5 billion, up almost 31 percent… Rinvoq's $2.1 billion revenues were up 23.3 percent." AbbVie CEO Robert Michael (an operator, quoted in the announcement) framed Apogee as building "on our existing leadership" in immunology. Read it plainly: the company that survived the largest biologic LOE in history is using the proceeds to defend the franchise that replaced it. **A banker named the cadence.** On J.P. Morgan's Making Sense, ["Dealmaking in healthcare: A mid-year pulse check"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjDiJYRckEiX1HdItt1L-2BebS7-2FOwg31bltDQ7gzRgjOtaqB92cj1TwrNHOb-2FUk09I5uHC3bP7K6vFGmvq15LGolA-3D-3Dz0l4_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpdjNRzGriC5xJtAVgBNk11O6E543o9W3r94h1meH82wT4DMX5fMN9NwnobPluHXpzviH-2BGXO68V96CqciU2jSZUIaMISnjut-2BVReQEVIKZkl1en1T-2FO3vmsMdLl2tx2-2FYQ-3D-3D) (June 26), global healthcare IB co-head Jerry Lee tied it all to the cliff: "every single large-cap pharma is staring at a different set of LOEs… they need to fill all of these LOEs. So the cycle continues. You've seen a number of large-cap pharmas almost do a deal every week now." Then the tell for anyone underwriting discipline: "investors… are relatively price insensitive about what their large-cap [pharmas] are paying because the durability of these LOEs is just so large." When the buy-side stops policing price, premiums like Apogee's 49% stop looking like outliers. **The IPO and follow-on window is the widest in years.** Same JPM episode, ECM's Haley Trethewey: "we just saw over $150 billion raised across sectors in the matter of 10 days… It's already been the most active year for biotech IPO activity since 2021… and we're only halfway through the year." Lee added that XBI "is at five-year highs," with the bank leading "the largest ever biotech follow-on for Revolution Medicines" and "the largest ever biotech IPO for Kylara" in the same week. Capital formation and M&A are feeding each other. **The seller's view on how Pfizer actually won MetSera.** The week's best insider color came from Running Through Walls, ["Building a Differentiated Obesity Biotech"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOissi7CtTciN2JzJO3lRXyF1UmUHMnFeuBC3grAdrVPIS1wadCx-2Fr3BB18xDbmh2eTHyeQpQkHT3QJuHhH2vUpYfYfvUbRQcYyEJEL4SzAG9A-3D-3DYRZV_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpezk1b9v8TSyzKpYtQwSN1gNEE0tPuDnxQhjxTsAjvxqvhRpY638f9XZYF9W7tpWm8lnLDGnd-2BdenKaZDgQMCSMllr-2BXFxXjl9EG1Cc68G7jGUqV-2B5KCDTV1RnbIxmhQIQ-3D-3D) (June 23), where MetSera CEO Whit Bernard (an operator who just sold to Pfizer) described the bidding war: Pfizer "moved really quickly and decisively," and then "what was a complete shock was basically a month later getting a letter from the CEO of Novo that they put in a topping bid, which really just doesn't happen in biopharma." Bernard tied the whole thing back to the cliff: MetSera's tech had to "address a revenue gap associated with a patent cliff in 2029, 2030, which is ultimately the problem that our colleagues at Pfizer needed to solve strategically." **The debate** This was a one-sided tape, and it's worth saying so. **The supercycle bull case** owned the week, a record-pace deal market (PwC's Roel van den Akker, on ["US Pharma Deals Midyear Outlook 2026"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiD0opUqOw1sRTQ0EBvtLlVSgpr4-2BzbWunQoYQURqiCD0ZoUvE0sZ67FYIkqaGY-2FsvBsgL7ou0frWIZxQ5cDBa8HEfUbCF4fYpQN6P4woduKA-3D-3D0oSS_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpWKYuSNlu1gs94NKZAelKQOTEjN2RphI1KtaOWHHkzTLfVGFQSYWvqqyyyQhBvzOJeQ-2BzTITUSaeEqGkWKEPlJ85ZWXXepFOAYsr1Dm0Qz1Q91WPtObMe6eVV-2FK6uy7lFw-3D-3D), June 24: extrapolating Q1 "you probably get a record year for biopharma M&A," with "over 20 transactions north of a billion dollars" through May), a banker calling the deal cadence weekly, and IPO windows at multi-year highs. > "Investors… are relatively price insensitive about what their large-cap [pharmas] are paying because the durability of these LOEs is just so large." Jerry Lee, J.P. Morgan What was conspicuously *missing* this week is the counter-narrative that ran loud just seven days ago. There was no "patent cliffs are a myth" reframe, no investor whispering "bubble," and, still, no FTC domestic-challenge commentary. The single antitrust data point was structural, not regulatory-enforcement: Bernard noted Novo Nordisk faced "complexity… from [an] antitrust perspective" in pursuing MetSera given its GLP-1 dominance, while Pfizer "had an advantage in terms of the structural simplicity." When the only voice of caution is "the other bidder had an antitrust problem," the skeptics simply weren't in the room. **The names in play** - **ABBV / APGE**: the deal of the week. AbbVie pays up (49%, no CVR) to extend the IL-23/immunology franchise that backfilled Humira. Operator conviction, premium price. - **MRK**: still the cliff everyone watches. On Motley Fool's ["Big Pharma Has a Case of Merger Mania"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjyURSFmVXNpM6h7YYJpBXB34Q4DoQiWhxGUvL6KsBt0tYWUA5OTYERq5hlD-2FLb1LfPjuvr88NtLwRVappsEK4bVi1xNoPfVaOsk-2FDvTTuGXQ-3D-3DLlBk_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpSx2QM3E0De1pxHWV-2FUxd8TofnjoGtpC4gP2H-2F5vxZ7i7PecnJn2pEpPK-2FsF4w5TuhTTaf3ms1OWwiKHI449-2FH6PpjZpeU13BvNBWfjA-2Bk0-2B2bOzEG09kAVW5BvrHGwosw-3D-3D) (June 23), the worry was explicit: "Keytruda makes up more than half of its revenue. And that patent goes away in 2028… that tight timeline, it really leaves little room for error." - **LLY**: the enviable position, same episode: "one of the most favorable patent cliff exposures in the space… Mounjaro and Zepbound… are patented through 2036." Also a stalking-horse bidder (with Astellas) for Sangamo's assets out of bankruptcy. - **PFE**: won MetSera on speed and a cleaner antitrust path, solving a 2029 to 2030 GLP-1-era gap. A motivated, time-pressured buyer. - **ASND (Ascendis)**: the one SMID name a guest genuinely moved. Motley Fool flagged its Transcon time-release platform as a takeout draw: "it's not just the drug itself, but also some of the technology behind it that you could easily see one of the big pharma companies… grabbing it." **Read-throughs** - **CDMOs are riding the onshoring wave.** On Off Script: ["The Future of Global Biopharma Manufacturing Networks"](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjgzdTz2j1Oq4RlPeMIXcd-2B29WP6JWw6hm-2BHsYEIRPgoGgdXWd174Sy5FD8pTzCt7XGXR0WRg0gs5QC6Tr6dleVx-2FI5WOmjPpiCwRvbfWZlEQ-3D-3DEwNu_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbW69eAd9h5rw1LP9x8RnBEeq5pmMdq8apCfji2k-2FoAdpQVJTwjVMDpbeU8odCfSuQ67-2Fd0Q-2F3wR5avON2SxpBJyeaeHUFSAYixIqV05gOJufmZXS6B17ID-2BS3gcj-2BPb4wa2VfZMmeyBo9dp0oNJ341VqFpSZXctM1fUlpuT9aJG9w-3D-3D) (June 23), Samsung Biologics' Jeff Mason (an operator) described US large pharma "trying to regionalize and onshore, mostly due to… geopolitical pressures," and Samsung stepping into a Rockville, Maryland facility "already being used for commercial supply… by GSK." His structural read: customers now want "multiple nodes ready at launch at multiple scales," and increasingly a single vertically integrated supplier for drug substance, drug product, "and maybe even packaging." J.P. Morgan's Lee echoed the theme from the banker's chair: CEOs are "very focused on where they are sourcing API, how they're manufacturing." - **Biosimilar makers**: quiet. The Humira erosion math (-40%) is doing work in the AbbVie story, but no named biosimilar manufacturer surfaced as an investable read-through this week. - **Bankers / ECM**: the clearest beneficiaries on the tape: record follow-ons, the busiest biotech IPO year since 2021, and a deal-a-week M&A pipeline all flow straight to advisory and underwriting fees. **What changed** Last week the new wrinkle was a *counter-narrative*, the "patent cliffs are a myth" reframe and the first "bubble" whisper. This week that skepticism vanished from the tape, and the bulls pressed their advantage: AbbVie/Apogee reset the year's high-water mark for core biopharma, a banker openly described the deal pace as *weekly*, and capital markets hit five-year highs. The signal moved from "supercycle running, but here's why the cliffs may not bite" to "supercycle accelerating, and the only people raising a hand are pointing at the *other* bidder's antitrust problem." Worth watching for whether the skeptics come back, or whether price-insensitivity is now just the house view.